io the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditions Transaction expected to close in Q3 2026
=*=*=*=*=*=
当前为第25/25页
上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页